Detection of PSMA-avid Hematologic Malignancies in Patients Undergoing Prostate Cancer Staging With PSMA-PET Scan

Prostate-specific membrane antigen (PSMA) PET scans have evolved as an essential modality in the diagnosis and staging of prostate cancer. PSMA avidity has been detected in additional non-prostate tissues, the significance of which is still not fully understood. Our case series highlights 4 cases from the Brown Health patient population where non-prostate PSMA avidity was found to represent hematologic malignancy. In 3 of our cases, subsequent biopsy confirmed lymphoma at PSMA-avid sites. In another case, a previously known lymphoma was demonstrated as PSMA-avid on prostate cancer staging PSMA-PET scan. These cases highlight the potential use of PSMA-PET as a diagnostic adjunct in lymphoma and raise questions regarding the possible use of anti-PSMA therapy in these malignancies.

Authors

Institutions

Publication Details

Journal
Clinical nuclear medicine open.
Published
2025-12-01
DOI
https://doi.org/10.1097/nm9.0000000000000059
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Detection of PSMA-avid Hematologic Malignancies in Patients Undergoing Prostate Cancer Staging With PSMA-PET Scan

Ari Pelcovits, Ryan Snow, Benedito A. Carneiro, Anthony Mega et al.
Clinical nuclear medicine open.
Prostate Cancer Treatment and Research
article

Detection of PSMA-avid Hematologic Malignancies in Patients Undergoing Prostate Cancer Staging With PSMA-PET Scan

Ari Pelcovits, Ryan Snow, Benedito A. Carneiro, Anthony Mega, Galina Lagos, Sathwik Madireddy, Kim Amelsberg
article en

Abstract

Prostate-specific membrane antigen (PSMA) PET scans have evolved as an essential modality in the diagnosis and staging of prostate cancer. PSMA avidity has been detected in additional non-prostate tissues, the significance of which is still not fully understood. Our case series highlights 4 cases from the Brown Health patient population where non-prostate PSMA avidity was found to represent hematologic malignancy. In 3 of our cases, subsequent biopsy confirmed lymphoma at PSMA-avid sites. In another case, a previously known lymphoma was demonstrated as PSMA-avid on prostate cancer staging PSMA-PET scan. These cases highlight the potential use of PSMA-PET as a diagnostic adjunct in lymphoma and raise questions regarding the possible use of anti-PSMA therapy in these malignancies.

Clinical nuclear medicine open.Vol. 2(4)
John Brown University (US), Brown University (US)
Openalex Percentile: Top 42%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.